Novel thraustochytriaceae strains for producing biomaterials comprising long-chain polyunsaturated fatty acids

Through the heterotrophic growth and homologous recombination technology of the PB31 strain of the new strain of the Thrasychodaceae, the problem of high-value omega-3 and omega-6 fatty acid substitution in fish oil is solved, and efficient and sustainable bio-oil production is achieved, providing An economical and safe alternative source.

CN118974265APending Publication Date: 2024-11-15PHYCOIL BIOTECHNOLOGY INTERNATIONAL INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380015416.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-17
Filing Date
2023-01-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively replace high-value omega-3 and omega-6 fatty acids in fish oil, especially in the absence of sustainable and safe alternative sources in the context of resource depletion caused by climate change and overfishing.

Method used

A new strain of PB31, a microbial strain of Thrasychodaceae, was developed. Through heterotrophic growth conditions under low-intensity light, it was cultivated in a closed fermenter to achieve the production of high yields of DHA and other omega-3 and omega-6 fatty acids. And the fatty acid synthesis pathway is regulated through homologous recombination technology to improve the production rate of polyunsaturated fatty acids.

Benefits of technology

The efficient production of bio-oils such as ARA, EPA, DPA and DHA is achieved, which improves the production and economics of bio-oils and provides a sustainable alternative source.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974265A_ABST
    Figure CN118974265A_ABST
Patent Text Reader

Abstract

Provided herein are a microorganism of the thraustochytriaceae family and a method for preparing a bio-oil using the microorganism of the thraustochytriaceae family, and more particularly, a method for preparing a bio-oil using the microorganism of the Provided herein are Schizochytrium limacinum PB31 (PTA-123692) having bio-oil producibility and methods of making bio-oils, particularly bio-oils having a content of omega-3 and / or omega-6 long chain polyunsaturated fatty acids of 30 wt% or more based on total fatty acids, characterized by culturing the microorganism.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 300,101, filed on January 17, 2022, the disclosure of which is incorporated herein by reference in its entirety.

[0003] The present invention describes a microorganism with bio-oil production capability and a method for producing bio-oil using the microorganism. More specifically, the present invention relates to a method for producing oils with high-value ω-3 and / or ω-6 oils such as ARA, EPA, DPA and DHA. Background Art

[0004] Omega-3 fatty acids such as EPA and DHA play important biological roles in human cognition, eye and cardiovascular health. Fish such as salmon, sardines and mackerel contain high amounts of these fatty acids. In the near future, the demand for such fatty acids will exceed the supply, a phenomenon combined with the depletion of natural resources due to climate change, overfishing and environmental pollutants in the ocean, making it necessary to develop alternative, safe and sustainable sources of such ω-3 oils and long-chain polyunsaturated fatty acids for human consumption. The unicellular marine protist Thraustochytrids found in offshore brackish waters has been developed because it is rich in ω-3 fatty acids (mainly DHA) that contribute to a high total PUFA content and some additional amounts of ω-6 fatty acids DPA. Organisms of the Thraustochytriaceae family, particularly strains of the genera Schizochytrium, Aurantiochytrium, and Thraustochytrium, have been cultivated in closed fermenters to obtain high yields of omega-3 oils as an alternative source of fish omega-3 oils for human consumption and cellular biomass for animal feed. Summary of the invention

[0005] Technical issues

[0006] The present application discloses a novel thraustochytrid strain named PB31 isolated from the coastal waters of Hawaii Island for commercialization of biomaterials including DHA and its production process. The strain produces about 70-80% lipids, and DHA comprises 30-50% by weight of the lipids in commercial scale fermenters.

[0007] The process involves growing cells under low-intensity light, which results in a higher growth rate than conventional heterotrophic growth conditions. Applicant's U.S. Pat. No. 9,932,554 describes the process using a signature culture condition known as PSP. This condition combines conventional heterotrophic growth with low irradiance (less than 5 μmol photons / m 2 s 1 ) as a signal to activate photoreceptors in the cells. The light intensity of the process does not activate the photosynthetic machinery in the cells and is therefore different from mixotrophic growth. The process also includes culturing, collecting, drying, extracting and purifying the bioproduct derived from this novel strain of thraustochytrid.

[0008] The inventors of the present invention have also developed PB31 as a biotechnology platform to produce various high-value polyunsaturated ω-3 and / or ω-6 lipids. Effective nuclear transformation by homologous recombination and easy gene targeting are the key features of this platform. The inventors of the present invention have described the pioneering experiments of setting up a repeatable transformation system at various genomic loci in PB31. Targeted knocking-down, knocking-out, knocking-in and point mutation of fatty acid or polyketide synthase lipid biosynthetic pathway genes can synthesize customized polyunsaturated fatty acids in PB31.

[0009] Thraustochytridaceae PB31 can serve as a general platform for the production of valuable biomolecules, including high-value ω-3 and / or ω-6 oils such as ARA, EPA, DPA and DHA. Here, the inventors of the present invention demonstrate the usefulness of the system in the biosynthesis of modified ω-3 and / or ω-6 fatty acids.

[0010] Solution to the problem

[0011] An object of the present invention is to provide a microorganism having a high polyunsaturated fatty acid production rate and improving the efficiency of the cultivation process, thereby allowing economical production of bio-oil.

[0012] Another object of the present invention is to provide a method for preparing bio-oil using microorganisms.

[0013] In order to achieve the above object, the present invention provides a microorganism PB31 capable of producing bio-oil, also named Schizochytrium sp. PB31 (PTA-123692), also simply named PTA-123692 herein.

[0014] In addition, the present invention provides a method for preparing bio-oil, the method comprising the following steps: (1) culturing the microorganism PB31, and (2) extracting and separating bio-oil containing ω-3 and / or ω-6 polyunsaturated fatty acids from the cultured microorganism.

[0015] Advantageous Effects of the Invention

[0016] The present invention shows that oils with high value omega-3 and / or omega-6 oils such as ARA, EPA, DPA and DHA can be efficiently produced when microorganisms are used. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The morphological characteristics of PB31 are shown.

[0018] Figure 2 A phylogenetic analysis is shown, which places PB31 in a lineage that includes Schizochytrium, Aurochytrium, and Thraustochytriidae.

[0019] Figure 3 is a graph showing biomass production under different growth conditions.

[0020] Figure 4 is a graph showing the effect of salinity on PB31 biomass production.

[0021] Figure 5 Shown are cells grown on a shaker with variable speed.

[0022] Figure 6 It is a graph showing the production rate of PB31 in various raw materials.

[0023] Figure 7 is a graph showing the glucose tolerance of PB31.

[0024] Figure 8 is a graph showing the growth of PB31 in wastewater generated when processing raisins.

[0025] Fig. 9 The nucleotide sequence of the transforming DNA contained in plasmid pPB0128 is shown.

[0026] Fig.10 The nucleotide sequence of the PB31 codon-optimized S. cerevisiae SUC2 gene (ScSUC2) in plasmid pPB0136 is shown.

[0027] Fig.11 The nucleotide sequence of the PB31 codon-optimized S. hindustanus zeocin resistance gene in plasmid pPB0240 is shown.

[0028] Fig. 12A and 12B The nucleotide sequence of the transforming DNA contained in plasmid pPB0152 is shown.

[0029] Fig.13 The nucleotide sequence of the transforming DNA contained in plasmid pPB0218 is shown.

[0030] Fig.14 The nucleotide sequence of the transforming DNA contained in plasmid pPB0258 is shown. DETAILED DESCRIPTION

[0031] Unless otherwise limited herein, the singular forms "a / an", and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. In addition, where the terms "including / include", "having / has / with", or variations thereof, are used in the detailed description and / or claims, such terms are intended to be inclusive in a manner similar to the term "comprising". The transitional terms / phrases (and any grammatical variations thereof) "comprising", "comprises", "comprise", "consisting essentially", "consists essentially of", "consisting", and "consists of" may be used interchangeably.

[0032] The phrase "consisting essentially of" or "consists essentially of" indicates that a claim covers embodiments containing the specified materials or steps and also those that do not materially affect the basic and novel characteristics of the claim.

[0033] The term "about" means within an acceptable error range for a value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. When describing values ​​in this application and claims, unless otherwise indicated, it should be assumed that the term "about" means that the particular value is within an acceptable error range. In the context of compositions containing amounts of ingredients using the term "about," these compositions contain amounts of the ingredients with a variation (error range) of 0-10% (X ± 10%) around the value.

[0034] "Fatty acid" shall mean the free fatty acid, fatty acid salt or fatty acyl moiety in a glycerolipid. It should be understood that the fatty acyl group of a glycerolipid can be described in terms of the carboxylic acid or anion of the carboxylic acid produced when the triglyceride is hydrolyzed or saponified.

[0035] A "fixed carbon source" is a carbon-containing molecule, typically an organic molecule, present in solid or liquid form in a culture medium at ambient temperature and pressure that is available to the microorganisms cultured therein. Thus, carbon dioxide is not a fixed carbon source.

[0036] In the subsequent patent, the use of the term "microorganism" includes, but is not limited to, the following terms: "microalgae", "marine protists", "Thraustochytridaceae" and any other potential taxonomic classifications associated with the PB31 microorganism, such as Schizochytrium, Aurochytrium, Thraustochytrium and Thraustochytrium, as described herein. All taxonomic classifications used in this patent with respect to the PB31 microorganism are based on current taxonomic classifications and available phylogenetic information, but are not intended to limit the event that the criteria for the taxonomic classifications used in this patent are revised after the filing date of this application.

[0037] "Microalgae" is a eukaryotic microbial organism that contains chloroplasts or other plastids, and optionally can perform photosynthesis. Microalgae includes an obligate photoautotroph that cannot metabolize a fixed carbon source into energy, and a heterotroph that can grow by a fixed carbon source. Microalgae is included in a unicellular organism that separates from sister cells soon after cell division, such as Chlamydomonas, and bacteria, such as Volvox, which is a simple multicellular photosynthetic bacteria with two different cell types. Microalgae includes cells such as Chlorella, Dunaliella, and Prototheca. Microalgae includes other microbial photosynthetic organisms that show cell-cell adhesion, such as Agmenellum, Anabaena, and Pyrobotrys. Microalgae also comprise the group of unicellular microorganisms characterized by the presence of two flagella, or having immature tripartite flagella, or unicellular or colonial microorganisms having a flagellar stage in their life cycle, such as diatoms, dinoflagellates, and thraustochytrids.

[0038] With respect to recombinant cells, the term "knockdown" refers to a gene that has been partially inhibited (eg, inhibited by about 1-95%) with respect to the production or activity of the protein encoded by the gene.

[0039] "Oleaginous" cells are cells that are capable of producing at least 20% lipid by dry cell weight, either naturally or through recombinant or classical strain improvement. "Oleaginous bacteria" or "oleaginous microorganisms" are bacteria that contain oleaginous microalgae, especially eukaryotic microalgae that store lipids. Oleaginous cells also encompass cells that have had some or all of their lipids or other contents removed, and encompass both living and dead cells.

[0040] In the case of functional oils, "atlas" is the distribution of species or triglycerides or fatty acyl groups in the oil." fatty acid profile" is the distribution of fatty acyl groups in the triglycerides of oil, irrelevant to being connected to the glycerol backbone. Fatty acid profiles are usually determined by being converted into fatty acid methyl esters (FAME), then by carrying out gas chromatography (GC) analysis with flame ionization detection (FID). Fatty acid profiles can be expressed as one or more percentages of fatty acid in the total fatty acid signal, and the percentage is determined by the area under the curve of the fatty acid.

[0041] The terms "triglyceride," "triacylglyceride," and "TAG" are used interchangeably as known in the art.

[0042] In the present disclosure, ranges are stated in a shorthand manner to avoid having to list and describe each value within the range in detail. Where appropriate, any appropriate value within the range may be selected as the upper limit, lower limit, or terminal value of the range. For example, a range of 0.1-1.0 represents terminal values ​​of 0.1 and 1.0, and intermediate values ​​of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and all intermediate ranges within 0.1-1.0, such as 0.2-0.5, 0.2-0.8, 0.7-1.0, etc. When ranges, combinations of ranges, and sub-combinations (e.g., sub-ranges within the disclosed ranges) are used herein, specific embodiments thereof are intended to be expressly included.

[0043] In the present invention, microorganisms of the Thraustochytridaceae family have been isolated from shallow waters of the Hawaiian Islands in order to develop microorganisms as biotechnology platforms with the producibility of various high-value polyunsaturated ω-3 and / or ω-6 lipids.

[0044] Therefore, in one aspect, the present invention relates to PB31 having bio-oil producibility.

[0045] The microorganism PB31 of the present invention is a microorganism classified into the Thraustochytridaceae family, and has the ability to produce ω-3 and / or ω-6 polyunsaturated fatty acids.

[0046] The microorganism of the present invention is a microorganism isolated from shallow water of Hawaii Island, and may have a DNA sequence of the 18S rRNA gene represented by SEQ ID NO: 1. As a result of searching using NCBI (National Center for Biotechnology Information) BLAST, it was found to be a novel microorganism of the Thraustochytrium family, and was deposited in the American Type Culture Collection (ATCC) (Manassas, VA, USA) on December 01, 2016 as Schizochytrium PB31 with the accession number of PTA-123692.

[0047] According to the present invention, the bio-oil produced by PTA-123692, internally named PB31, is characterized in that it can be contained in 70wt% or more of dry biomass, and based on the weight of total fatty acids (TFA), the content of polyunsaturated fatty acids contained in the bio-oil can be 30 to 55wt%. The polyunsaturated fatty acids can be docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (ARA), eicosapentaenoic acid (EPA) or a mixture thereof, but preferably docosahexaenoic acid. Preferably, docosahexaenoic acid is characterized in that it is contained in 30wt% or more, preferably 30 to 50wt% relative to the total fatty acid content. The bio-oil produced by PB31 can further include saturated fatty acids, such as palmitic acid or other fatty acid components except polyunsaturated fatty acids.

[0048] In addition, as a result of analyzing morphological characteristics and biochemical characteristics to identify the microorganism of the present invention, PB31 according to the present invention has the characteristics of the genus Schizochytrium, which continuously divides into tetrads and octads before the cell produces zoospores, and produces irregularly shaped amoeba cells (see Figure 1 ).

[0049] The advantage of PB31 provided by the invention is that PB31 strain is a robust organism that grows rapidly and performs well under industrial / commercial scale fermentation conditions such as high pressure and high shear force. PB31 does not produce a large amount of other byproducts (such as polysaccharides) during incubation, and such byproducts interfere with optimal cell biomass and oil production rate. Another advantage is that the cell wall of PB31 is robust enough to withstand the high pressure in large-scale fermentation tanks, and does not require pretreatment or other steps during downstream processing to open the cells to extract oil. Another advantage is that organism can be easily and effectively transformed, and the simple gene targeting by homologous recombination can be repeated by being transformed on various genomic loci, thereby realizing the targeting of fatty acid or polyketide synthase lipid biosynthesis pathway genes to strike low, knock out, knock in and point mutation, and therefore, it can be used as a general industrial biotechnology and metabolic engineering platform, for producing valuable biomolecules, comprising high-value ω-3 and / or ω-6 oils, such as ARA, EPA, DPA and DHA.

[0050] In the present invention, when the microorganism PB31 and the bio-oil extracted therefrom are cultivated, the content of polyunsaturated fatty acids such as DHA in the biomass containing the microorganism is high, and the cells can be cultivated at a high concentration. This has the advantage that bio-oil containing a high content of polyunsaturated fatty acids can be obtained with a high production rate and a high yield.

[0051] In another aspect of the present invention, the present invention provides a method for using PB31 as a platform for producing polyunsaturated fatty acids.

[0052] In another aspect of the present invention, the present invention provides an industrial biotechnology platform for producing polyunsaturated fatty acids including PB31.

[0053] In the examples of the present invention, PB31 can be efficiently and reproducibly converted using a modified lithium acetate (LiAc) conversion method.

[0054] Additionally, homologous recombination occurs in PB31 and can be used as a tool to modulate various enzyme activities through gene knockdown, knockout, and knockin.

[0055] Homologous recombination in PB31 can be used to enhance or inhibit target gene activity by replacing endogenous regulatory elements with up-regulated or down-regulated heterologous regulatory elements.

[0056] Specific point mutations can be introduced into endogenous enzymes to effect changes in the catalytic activity of the target enzyme, resulting in enhanced product profiles or even novel products.

[0057] The optimal combination of homologous recombination-based gene knockdown, knockout, and knockin, together with specific point mutations and / or modulation of endogenous regulatory elements, will generate a novel product profile in PB31.

[0058] Yet another aspect of the present invention relates to the use of the PB31 of the present invention, the biomass comprising the PB31, or the concentrate or dry product of the biomass or bio-oil separated from the microorganism in the production of food, beverages, nutritional preparations, pharmaceutical preparations, animal feed or cosmetics.

[0059] Specifically, the PB31 provided in the present invention, the biomass comprising the PB31, or the concentrate or dry product of the biomass can be used in animal feed (especially added or mixed in feed for cattle, pigs, chickens, goats, sheep and pet food) or aquatic animal feed without further purification or treatment.

[0060] Therefore, in another aspect, the present invention provides a feed composition comprising the group consisting of: PB31, a biomass obtained by fermenting PB31, a concentrate of the biomass, and a dried product.

[0061] In another aspect, as another aspect, the present invention relates to a method for producing biomass using PB31. The method for producing biomass of the present invention is characterized by comprising the steps of culturing and fermenting PB31.

[0062] The culture of PB31 in the above production method can be carried out using a culture method such as conventional heterotrophic fermentation, a closed photobioreactor or an open pond system.

[0063] In a specific aspect, the production method according to the invention is characterized by culturing Schizochytrium sp. PB31 (PTA-123692) under conditions giving a light signal with a light intensity in a specific range in the culture. Preferably, the light intensity means the amount of light that prevents very weak light from being cultivated in autotrophic mode or mixotrophic mode, specifically 0.1 μmol / m 2 ·s to 5 μmol / m 2 ·s, 0.1μmol / m 2 ·s to 4 μmol / m 2 ·s, 0.1μmol / m 2 ·s to 3 μmol / m 2 ·s, 0.5μmol / m 2 ·s to 5 μmol / m 2 ·s, 0.5μmol / m 2 ·s to 4 μmol / m 2 ·s, 0.5μmol / m 2 ·s to 3 μmol / m 2 ·s, 1μmol / m 2 ·s to 5 μmol / m 2 ·s, 1μmol / m2 ·s to 4 μmol / m 2 ·s, 1μmol / m 2 ·s to 3 μmol / m 2 ·s or 2μmol / m 2 ·s to 5 μmol / m 2 s. The light signal may be continuous or discontinuous light, may irradiate full spectrum light not limited to a specific wavelength range, or may give light of a specific wavelength. In the case of culturing by giving a light signal with a light intensity within this specific range, the microorganism according to the present invention may be cultured in a heterotrophic mode, rather than in an autotrophic mode or a mixed trophic mode.

[0064] In a particular aspect, blue light can be used for the production method. Specifically, the wavelength of the light can be 400 to 500 nm, 450 to 500 nm, or 450 to 490 nm.

[0065] In order to cultivate PB31, it is preferred that the carbon source is supplied together with the culture medium. The culture medium for cultivation is not limited, as long as it is a culture medium for cultivating microorganisms, and may preferably contain seawater. The carbon source may be any carbon source suitable for cultivating microorganisms without restriction, and it may preferably be monosaccharides such as glucose, fructose, galactose or mannose; disaccharides such as sucrose, pentoses (such as arabinose and xylose); sodium acetate; glycerol; crude glycerol, etc., and most preferably glucose.

[0066] Preferably, the carbon source is supplied in a continuous or batch-feeding mode to maintain an appropriate concentration. If necessary, methods such as pH-stat or DO-stat can be used, or the concentration of each carbon source can be measured in real time and supplied when necessary.

[0067] Examples of such nutrient components include various nitrogen sources, phosphate sources and other components, which are obvious to those skilled in the art. In addition, as examples of culture media, it is also obvious to those skilled in the art that complex culture media or defined culture media can be used.

[0068] The nitrogen source may comprise an organic nitrogen source, such as yeast extract, corn steep liquor, beef extract, malt extract, peptone and tryptone; or an inorganic source, such as ammonium acetate, ammonium nitrate, ammonium chloride, ammonium sulfate, sodium nitrate, urea or MSG.

[0069] It is preferred that the pH and / or temperature be maintained within a preset range while culturing PB31 by the above-mentioned culturing method. As a method for maintaining a constant pH and / or temperature during culturing, methods known in the art can be used. For example, the following methods can be used but are not limited to: a method using a cooling jacket using cooling water, a method using a pH controller to automatically supply acid or alkali, etc.

[0070] Preferably, the concentrations of chloride, sodium ion and potassium ion contained in the culture medium may be 0.6 to 0.8 g / L, 5.0 to 7.0 g / L and 0.4 to 0.6 g / L, respectively, and the culture may be performed at pH 6 to 8. The acid used for adjusting the pH may preferably be sulfuric acid, acetic acid or a mixed acid thereof.

[0071] In a preferred embodiment, the microbial culture produced by the above production method can be collected by methods such as centrifugation, flocculation, flotation and filtration. After collecting the microbial product, several drying methods such as spray drying and drum drying can be used to obtain culture powder.

[0072] In another aspect, the present invention provides a method for preparing bio-oil, the method comprising the following steps: (1) culturing PB31, and (2) extracting and separating bio-oil containing ω-3 and / or ω-6 polyunsaturated fatty acids from the cultured microorganism.

[0073] In the present invention, the culture in the above step (1) may be performed in a manner selected from the group consisting of batch culture, fed-batch culture and continuous culture, and in the above step (2), a cell disruption step may be further included.

[0074] The cell disruption may be cell disruption using an ultrasonic disperser, cell disruption using a pulsed electric field, cell disruption using an enzyme, cell disruption using osmotic pressure, cell disruption using an electron beam, or cell disruption using an organic solvent.

[0075] The method for preparing the bio-oil of the present invention may further include (3) purifying the bio-oil containing ω-3 and / or ω-6 fatty acids.

[0076] In the present invention, purification may include collecting only the oil phase among the oil phase containing the bio-oil and the water phase containing the cell sheets, and may be performed by one or more steps including removing a solidified oil fraction, bleaching using bleaching clay or activated carbon, filtering, and deodorizing.

[0077] In the present invention, the deodorizing step may be performed by a steam deodorizing process under reduced pressure.

[0078] In one embodiment of the present invention, the method for preparing bio-oil containing ω-3 and / or ω-6 fatty acids using PB31 may include the following steps:

[0079] (1) culturing PB31; and

[0080] (2) Collecting the cultured cell biomass, and extracting and separating the bio-oil containing ω-3 and / or ω-6 polyunsaturated fatty acids.

[0081] The method may further comprise:

[0082] (3) Purifying the bio-oil containing separated ω-3 and / or ω-6 polyunsaturated fatty acids.

[0083] Hereinafter, each step will be described in detail.

[0084] The culture of PB31 in the above step (1) can be carried out in a manner selected from batch culture, fed-batch culture and continuous culture, and preferably, fed-batch culture or continuous culture is used.

[0085] In step (1), it is preferred to supply the carbon source for cultivating PB31 by batch feeding culture or continuous culture. Herein, only when the carbon source uses PB31 to grow, the carbon source can be used without restriction, and glucose, fructose, sucrose, galactose, glycerol, crude glycerol as biodiesel waste, etc. (but not limited to this) are preferred, and glucose is the most preferred. It is preferred to supply the carbon source in a continuous or batch feeding mode so as to maintain a suitable concentration, and if necessary, methods such as pH-stat or DO-stat can be used, and methods such as the concentration of each carbon source can also be used to supply the carbon source as required by measuring the concentration of each carbon source in real time, etc. In addition, the nutrients required for the growth of PB31 can be contained in the culture medium, and it is obvious to those skilled in the art that various nitrogen sources, phosphate sources, other components, etc. can be contained, and complex culture medium, defined culture medium, etc. can also be used. As the nitrogen source, organic nitrogen sources such as yeast extract, corn steep liquor, beef extract, malt extract, peptone, trypsin, etc., and inorganic nitrogen sources such as acetate, ammonium nitrate, ammonium sulfate, sodium nitrate, urea, etc. can be used.

[0086] Specifically, it is preferred to set the salt concentration to an appropriate concentration level and perform culturing within the range.

[0087] In step (1), it is preferred to maintain the pH and / or temperature within a predetermined range during the culture of PB31 by batch feeding or continuous culture. As a method for constantly maintaining the pH and / or temperature during the culture, methods well known in the art, such as a method using a cooling jacket using cooling water, a method using a pH controller to automatically supply an acid or a base, etc., can be used but are not limited thereto.

[0088] In addition, it is preferred to culture PB31 by batch feeding or continuous culture under sufficient ventilation and stirring. The ventilation speed and stirring speed can be appropriately selected by those skilled in the art according to the process conditions. More specifically, since PB31 is aerophilic and has a weak characteristic under shear stress generated by stirring, it is preferred that the stirring speed can be selected from 50-300rpm, preferably 100-300rpm, and the ventilation speed can be 0.5-5vvm, preferably 1-3vvm.

[0089] The content of ω-3 and / or ω-6 polyunsaturated fatty acids in the bio-oil produced by the culturing according to step (1) of the present invention is 30 wt% or more, preferably 40 wt% or more, most preferably 50 wt% or more, based on total fatty acids.

[0090] The step of collecting the cultured PB31, and extracting and separating the bio-oil containing ω-3 and / or ω-6 polyunsaturated fatty acids according to step (2) include the step of disrupting the cells after completing the culture in step (1). In the step of cell disruption, cell disruption can be induced by methods such as cell disruption using a pulsed electric field, cell disruption using an enzyme, and cell disruption using an electron beam (but not limited thereto), and it is obvious to those skilled in the art that a method of disrupting the cells and extracting the oil using an organic solvent such as hexane can be used. Specifically, if a disruption technique is used after cell disruption using osmotic pressure, the cell disruption effect can be enhanced.

[0091] As the cell disruption proceeds, the oil phase is phase-separated from the aqueous phase containing the cell pieces, and only the oil phase is collected at this time, and the final bio-oil product can be obtained through the purification process in step (3).

[0092] The purification of the bio-oil according to step (3) is carried out by comprising one or more steps selected from the group consisting of: keeping the oil phase at -5-0°C for 5-20 hours to remove the solidified oil fraction, bleaching the oil fraction using bleaching clay and / or activated carbon, filtering and deodorizing, and preferably, these steps can be performed in sequence.

[0093] It is preferred to perform filtration using a filter having a pore size of 0.5-1 μm, and it is also preferred to perform deodorization by a steam deodorization process under reduced pressure, but not limited thereto.

[0094] The bio-oil produced according to the production method of the present invention is not limited thereto, but may contain about 30 to 55 wt % of polyunsaturated fatty acids, preferably 30 wt % or more of total fatty acids (TFA). Preferably, it may contain 30 to 55 wt % of docosahexaenoic acid.

[0095] Invention Mode

[0096] [Example]

[0097] Hereinafter, the present invention will be described in detail by the following examples. These examples are only used to specifically illustrate the present invention, and it is obvious to those skilled in the art that according to the spirit of the present invention, the scope of the present invention is not limited to these examples.

[0098] I. Isolation of Microorganisms

[0099] PB31 was isolated from fallen leaves in shallow offshore seawater. After washing with sterile seawater, the collected leaves were cut into small rectangular pieces and soaked in the same seawater at room temperature for 24 hours. 1 ml of this seawater was transferred to each well in a 12-well plate containing 2 ml of seawater, 0.3% yeast extract, 2% glucose, and 300-600 μg / ml penicillin and streptomycin. Several washed leaves were placed on a seawater agar plate containing 0.3% yeast extract, 2% glucose, 600 μg / ml penicillin G, and 600 μg / ml streptomycin. After several rounds of dilution into a new 12-well plate and streaking onto a new agar plate, the inventors of the present invention were able to obtain a single sterile cell culture. Each colony isolated from the agar plate was transferred to a new agar plate and grown to confluence. Once the cells on the agar plate are subjected to a pollution check, the cells are collected and expanded into a 125 ml flask containing 50 ml of culture medium, and grown four days on an orbital shaker at 150 rpm under PSP conditions at room temperature. Along with cell growth, the color of the culture becomes light yellow, white yellow or light cream yellow. After the pollution check, a certain amount of cell culture is transferred to a new flask to maintain, and remaining cell culture is transferred to a clean 50 ml falcon tube, and centrifuged at maximum speed for 3 minutes to collect cell pellets. Pellets are freeze dried and stored in a refrigerator at -20 ° C for further analysis.

[0100] II. Identification of Microorganisms

[0101] PB31 cells grown for 4 days in basal growth medium containing 2% glucose were harvested by centrifugation. The basal growth medium consisted of 1 L of the following: 13.5 g Na2SO4, 1.5 g NaCl, 2.57 g MgSO4 7H2O, 0.3 g CaCl2, 0.75 g NaNO3, 3 g yeast extract, 2.38 g HEPES, 0.027 g NH4Cl, 10 ml stock trace metal solution, 1 ml chelated iron solution, 80 ml 0.1 M phosphate solution (pH 7.8), and 1 ml vitamin solution. The stock trace metal solution consisted of 100 ml of the following: 0.1 g Na2EDTA 2H2O, 0.114 g H3BO3, 4.9 mg FeCl3 6H2O, 1.92 mg MnCl2 4H2O, 2.2 mg ZnSO4 7H2O, and 0.48 mg CoCl2 6H2O. The stock chelated iron solution consisted of 100 ml of the following: 0.5 g Na2EDTA, 10 ml 1 M HCl solution, and 0.081 g FeCl36H2O. The sterile stock vitamin solution consisted of 200 ml of the following: 50 mM HEPES (pH 7.8), 0.44 g thiamine-HCl, 0.005 g biotin, 0.027 g B12, and 0.619 g D-hemi-calcium pantothenate. The stock phosphate solution consisted of 1 L of: 90.8 ml 1M K2HPO4 and 9.2 ml 1M KH2PO4.

[0102] The isolated strains showed characteristics of microorganisms belonging to the Thraustochytridaceae family through microscopic observation and isolation from single colonies in agar plates.

[0103] Some zoospores with two flagella were observed, especially in the early growth period or when glucose was not present in the medium. Growing cells actively divide into dyads, tetrads, and octads, and once they enter the stable growth period, oil droplets accumulate in the cells ( Figure 1 ). Literature search showed that Schizochytrium is characterized by continuous bisection of cells into tetrads and octads before zoospore production. Schizochytrium also produces "irregularly shaped amoeboid cells" (Mycosphere, Cultural optimization of Thraustochytrids for Biomass and Fatty Acid Production, 2011). These observations suggest that the novel PB31 strain described in this patent may be Schizochytrium.

[0104] To determine the genetic identity of the patented strain, genomic DNA was extracted from PB31 using CTAB and phenol / chloroform / isoamyl alcohol protocols, and a portion of the 18S rRNA gene was amplified using primers PB00020 and PB00021 (Honda et al. 1999) using a Herculase II fusion DNA polymerase enzyme and a dNTP combination kit (Agilent, USA), and then the amplified PCR product was subjected to Sanger sequencing (Genewiz, USA). The primer sequences for amplifying 18S rRNA are shown below.

[0105] PB00020 forward: 5'-AACCTGGTTGATCCTGCCAGTA-3' (SEQ NO.: 3)

[0106] PB00021 reverse: 5'-CCTTGTTACGACTTCACCTTCCTCT-3' (SEQ NO.: 4)

[0107] The PCR protocol consists of the following steps:

[0108] 1) 95℃ for 2 minutes,

[0109] 2) 95℃ for 20 seconds,

[0110] 3) 50℃ for 20 seconds,

[0111] 4) 72°C for 1 minute, repeat steps 2 to 4 30 times,

[0112] 5) 72°C for 3 minutes, and

[0113] 6) 24°C for 1 minute.

[0114] Pairwise comparison of the 18S ribosomal RNA gene sequences of PB31 (SEQ 1 and SEQ 2) showed that PB31 was closely related to Schizochytrium, Thraustochytriidae sp., and Aurantiochytrium sp. (Tables 1 and Figure 2 ).

[0115] [Table 1]

[0116] Comparison of 18S rRNA sequence with partial 18S rRNA sequence of PB31

[0117]

[0118] Comparison of 18S rRNA sequences with the common 18S rRNA sequence of PB31

[0119]

[0120] Comparison of the PB31 18S rRNA sequence with sequences in the National Center for Biotechnology Information (NCBI) database.

[0121] III. Growth Experiments and Media Optimization

[0122] The initial inoculum was placed in a 250 ml Erlenmeyer flask containing 100 ml seawater, 0.3% yeast extract and 2% glucose at room temperature in a PSP shaker (a custom-made 6-12-channel light source with a light intensity of 0.1 to 1 μmol photons / m 2 s 1 After 48 hours of growth in the initial flask, 5 ml of the cell culture was transferred to three new flasks containing 95 ml of basal growth medium and 2% glucose. The incubator shaker was prepared as follows: one flask was designated for the dark shaker, one flask was prepared for the shaker equipped with a blue LED bulb under PSP experimental conditions, and the last flask was maintained at 35 μmol photons / m 2 s 1 The cell cultures were grown for 4-5 days under white light conditions until all the fed glucose was consumed. 1 ml of cell culture was collected from each flask to measure the biomass and glucose consumption each day. Figure 3 As shown. Growth under PSP conditions produced the highest biomass compared to dark conditions. Based on lipid data, blue light conditions produced the highest production rate, as well as higher DHA production (Table 2).

[0123] [Table 2]

[0124]

[0125] Comparison of fatty acid profile data between PSP conditions and heterotrophic conditions.

[0126] Unless otherwise stated, the following sets of experiments were performed to optimize the medium for optimal growth of PB31 at room temperature and 150 rpm in a PSP shaker.

[0127] 1. Salinity

[0128] The initial inoculum was prepared as described above. 5 ml of the initial inoculum was transferred to four 250 ml baffled flasks containing 95 ml of basal growth medium containing different Na2SO4 concentrations (12, 17, 22 and 27 g / L), 30 mM MSG and 4% glucose. Cell growth was measured by collecting 1 ml samples from the flasks every day to measure biomass and glucose consumption from day 4 to 6, or until all glucose was consumed. Based on experimental data, 17 g / L Na2SO4 produced the best growth ( Figure 4 ).

[0129] 2. Dissolved oxygen levels

[0130] Two incubator shakers were set up: one shaking at 150 rpm and the other shaking at 190 rpm. Flasks containing 100 ml of cell culture were incubated for 3 days. Cell growth under different conditions was measured in the same manner as described above. By using a faster shaker speed, the inventors were able to shorten the growth by nearly 24 hours (0.02 hours) when compared to a speed of 150 rpm. Figure 5 ).

[0131] 3. Carbon source

[0132] Monosaccharides (glucose, fructose, galactose and mannose), Disaccharides (sucrose) and 5-carbon sugars (arabinose and xylose) were used to test the growth of PB31. Other commonly used carbon sources, such as sodium acetate and glycerol, were also tested in combination with glucose or tested alone. In 6-well plates, cells were incubated with 1% of various carbon sources. Xylose and arabinose were tested in combination with 1% glucose. Different ratios of glucose and glycerol mixtures were tested in 250 ml flasks, where the total working carbon source concentration reached 2% to 4% (w / v) in the cell culture.

[0133] Glucose produced the best production rate in the 6-well plate experiment compared to the other feedstocks tested. Glycerol was the second best carbon source used by the cells. Other carbon sources such as galactose, fructose, and mannose also produced good growth. The use of a mixture of five-carbon ring sugars (arabinose or xylose) with glucose did not produce any additive effect when compared to samples using glucose alone ( Figure 6 ).

[0134] PB31 was grown in medium containing different concentrations of glucose (20 g / L, 40 g / L, 60 g / L, 80 g / L, and 100 g / L) to determine its glucose tolerance level ( Figure 7The experiment was conducted for 5 days. Although the best biomass production rate was achieved with 20 g / L glucose, PB31 tolerated higher concentrations of glucose (up to 100 g / L) well without significant effects on its growth characteristics, indicating that PB31 can grow efficiently in highly concentrated glucose solutions.

[0135] The flask data of PB31 showed that the growth of 2 (w / v)% glycerol (16.7 mg / ml, 51.68%) was higher and the DHA (C22:6n3) production rate was higher (Table 3) compared with 2 (w / v)% glucose (12.8 mg / ml, 40.33%). When compared with the results reported by others (US20090117194; data of people such as Burja), the present invention achieved higher biomass, total fatty acids and DHA production rates. 4% (w / v) of glycerol caused a further increase in DHA, TFA and biomass. Glucose-glycerol mixtures of different ratios also performed better than glucose alone, where the increase seen in TFA, DHA and biomass depended on the increase in glycerol concentration.

[0136] [Table 3]

[0137]

[0138] Fatty acid profile and lipid production rate of PB31 in shake flasks grown on glucose, glycerol or a mixture of both.

[0139] 4. Nitrogen source

[0140] Different ratios of inorganic and organic nitrogen sources were tested for the growth of PB31. For inorganic nitrogen, the inventors of the present invention changed the sodium nitrate concentration, ammonium chloride concentration, and MSG concentration in the culture medium to determine its effect on biomass and DHA production rates. For organic nitrogen sources, the inventors of the present invention changed the percentage of yeast extract in the culture medium from 0.1% to 0.3% (w / v). The best biomass production rate and DHA percentage were achieved with 20mM NaNO3+0.5mM NH4Cl+0.3% yeast extract+30mM MSG. However, due to the high total nitrogen content in the culture medium used, this condition resulted in the lowest total fatty acid percentage (Table 4).

[0141] [Table 4]

[0142]

[0143] Effect of nitrogen source on lipid production rate and fatty acid profile of PB31 in shake flasks.

[0144] 5. Wastewater as a carbon source

[0145] 2 L of wastewater was obtained from Lion Raisins (Selma, CA), which was derived from water used to wash dried grapes and contained approximately 2-4% glucose. PB31 was grown under different conditions using the raisin wastewater to compare its growth with the basal growth medium. The conditions tested were as follows.

[0146] 1) Basic growth cell culture medium + 2% (w / v) glucose

[0147] 2) Wastewater + NaNO3 (same concentration as in #1)

[0148] 3) Wastewater only (RW) (Raisin wastewater)

[0149] 4) 25% (v / v) wastewater (25% wastewater + 75% basal growth medium)

[0150] 5) 50% (v / v) wastewater (50% wastewater + 50% basal growth medium)

[0151] 6) 75% (v / v) wastewater (75% wastewater + 25% basal growth medium)

[0152] Cell cultures were grown in 6-well plates for 4 days and growth was monitored by measuring the optical density of the cell cultures on days 3 and 4.

[0153] The growth of PB31 on raisin wastewater was comparable to that on conventional media. The mixture of basal growth medium and 25-50% (v / v) raisin wastewater produced the highest growth, indicating the possibility of utilizing wastewater in large-scale fermentation of PB31 ( Figure 8 ).

[0154] III. Mutagenesis

[0155] UV light is used to make PB31 cells undergo random mutagenesis, and then triclosan (Triclosan) is processed to improve growth rate and lipid production. Four 10ml PB31 cultures in logarithmic growth phase are placed on a petri dish (Petridish), and are placed in a biosafety hood 10-15cm away from a UV bulb, for 14-60 minutes. The 1ml basal growth medium from each condition is diluted with 1:10,000, and spread onto an agar plate containing 1-10mM triclosan. From each plate, select about 3-5 bacterium colonies, and grow them on 6-well plates. Growth rate is monitored by measuring the optical density at 750nm, and glucose consumption is monitored by using a UV spectrophotometer to measure the optical density at 340nm.

[0156] 3 samples showed faster glucose consumption and growth rate. These strains were named PB31-2, PB31-4 and PB31-5. In flask and 5L fermenter experiments, compared with wild-type cells, the mutagenized strains also produced higher amounts of lipids and DHA (Tables 5 and 6).

[0157] [Table 5]

[0158] Sample optical density (750nm) Residual glucose (g / L)

[0159]

[0160] Growth and glucose assay results measured by optical density indicate the remaining level of glucose in the cell culture medium.

[0161] [Table 6]

[0162]

[0163] Lipid profiles of mutagenized cells in flask and 5-L fermentor experiments.

[0164] Fed-batch 5000L fermentation and optimization of PB31-4.

[0165] PB31-4 was grown for 5 days in a 5000 L commercial scale fermentor custom equipped with a low irradiance light strip to provide PSP conditions. The large scale fermentor medium consisted of the following in a range in 1 L of water: 13-17 g Na2SO4, 1.5 g NaCl, 3-6 g MgSO4 7H2O, 0.3 g CaCl2, 1.7 g NaNO3, 3-5 g yeast extract, 12-20 g MSG, 0.027 g NH4Cl, 10-20 ml stock trace metal solution, 1-2 ml chelated iron solution, 80 ml 0.1 M phosphate solution (pH 7.8), and 4 ml vitamin solution. The stock trace metal solution consisted of 100 ml of the following: 0.1 g Na2EDTA2H2O, 0.114 g H3BO3, 4.9 mg FeCl3 6H2O, 1.92 mg MnCl2 4H2O, 2.2 mg ZnSO4 7H2O, and 0.48 mg CoCl2 6H2O. The stock chelated iron solution consisted of 100 ml of the following: 0.5 g Na2EDTA, 10 ml 1 M HCl solution, and 0.081 g FeCl3 6H2O. The sterile stock vitamin solution consisted of 200 ml of the following: 50 mM HEPES (pH 7.8), 0.44 g thiamine-HCl, 0.005 g biotin, 0.027 g B12, and 0.619 g D-hemi-calcium pantothenate. The stock phosphate solution consisted of 1 L of: 90.8 ml 1M K2HPO4 and 9.2 ml 1M KH2PO4. The pH was adjusted using 8% NaOH, 8% KOH, and 10% H2SO4 solution. 50 ppm of defoamer was used to control bubbles and foam produced during fermentation. During the lipid production step, the dissolved oxygen level was maintained below 1.

[0166] As shown in Table 7, the results of eighteen runs of PB31-4 in a large-scale fermenter demonstrated consistent production of over 70 wt% total oil and 45 wt% DHA oil in the biomass.

[0167] [Table 7]

[0168]

[0169] Scale-up of PB31-4 in a 5000 L large-scale fermenter.

[0170] Lipid extraction and fatty acid profiling

[0171] Total lipids were extracted from freeze-dried cell pellets grown in 250 ml flasks. About 2 g of sample in a 50 ml falcon tube was treated with 5 ml HCl acid in an 80 ° C water bath for about 1 hour with occasional shaking. After the sample cooled, 35-40 ml of ether was added to the falcon tube, vortexed and centrifuged at maximum rpm. The upper solvent layer was collected in a round-bottomed flask. The extraction with ether was repeated 2 more times. 30 ml of petroleum ether was added to the falcon tube, vortexed and centrifuged subsequently. The upper solvent layer was collected and the ether solvent in the round-bottomed flask was evaporated using a rotary evaporator.

[0172] 25mg of the extracted oil is transferred to a 5ml glass vial. 1ml isooctane and 2ml 14% boron trifluoride (BF3) are added to the sample, then incubated on a 100°C heating block for one hour. After adding 5ml saturated NaCl solution and 1ml isooctane, the cooled methylated oil sample is transferred to a 15ml falcon tube. After vortexing and centrifugation, the upper oil layer is collected in a microtube for GC chromatography. Then, the sample is analyzed using the 7890A GC system of Agilent Technologies.

[0173] The fatty acids extracted from PB31 cells are mainly composed of palmitic acid and DHA. Palmitic acid accounts for nearly 51% of the total fatty acids (TFA), while DHA accounts for the remaining 49% of TFA. Palmitic acid and DHA are also the dominant fatty acids produced by S. limacinum (Yokochi et al., 1998), S. mangrovei (Fan et al., 2001), T. aureum (Bajpaj et al., 1991; Iida et al., 1996) and Thraustochytrium sp. (Singh et al., 1996).

[0174] For the fermentation product (5000L) with higher concentration and larger volume, PB31 is grown under PSP conditions to produce the maximum amount of algae bioproduct. PB31 can be cultured on a large scale using culture methods such as traditional heterotrophic fermentation, closed photobioreactor or open pond system. Algae culture can be collected by using centrifugation, flocculation, flotation or filtration. After collecting the algae product, several drying methods (such as spray dryer and drum dryer) can be utilized to obtain algae powder. Algae culture can be used directly without the need to collect algae sludge before the drying step, depending on which drying method will be adopted for specific application. Supercritical fluid extraction method is used for 5000L fermentation tank product, but organic chemical solvents such as Soxhlet or hexane extraction or mechanical methods such as press squeezing or ultrasound-assisted extraction can be used to extract total oil product from algae powder.

[0175] PB31 cells consist of 40-80% fat, 5-40% carbohydrates and 10-50% protein. Algae products such as extracted oils contain hydrocarbons, carotenoids and further purified ω-3 and / or ω-6 fatty acids, which can be used as processing materials for food ingredients (especially chocolate) and additives, health supplements, drugs and cosmetic ingredients. Algae powder can be used in animal feed (especially added or mixed into feed for cattle, pigs, chickens, goats, sheep and pet food) and for aquatic animals without further processing, purification or treatment steps. In addition to animal feed, carbohydrates and proteins in algae (such as dietary fiber and polysaccharides, oligopeptides, protein extracts and essential fatty acids) can also be used in cosmetics, bioplastic materials and functional ingredients, such as algae powder, vitamins and minerals.

[0176] IV. Metabolic Engineering

[0177] 1. Transformation and recovery of PB31 recombinant strain.

[0178] Establishing a versatile and reproducible transformation system is a critical first step in regulating the production of various bioproducts in PB31. EF1α is one of the most highly expressed genes in Thraustochytridaceae organisms. To take advantage of its high expression, the inventors of the present invention attempted to use this locus as a landing pad for transformation into the PB31 nuclear genome and selected the co-opted EF1α promoter and 3' untranslated region to drive the expression of various marker genes. This was achieved by disrupting or knocking out the endogenous EF1α gene and replacing it with neomycin, sucrose invertase or bleomycin marker genes.

[0179] This example describes recombinant strains recovered after transformation of PB31 with plasmids pPB0128, pPB0136, and pPB0240, which contain the Saccharomyces cerevisiae neomycin resistance gene, the Saccharomyces cerevisiae sucrose invertase gene, and the Streptoalloteichus hindustanus bleomycin gene, respectively, under the control of the elongation factor 1α promoter and terminator regions amplified from PB31 genomic DNA.

[0180] Based on the genomic sequences of closely related strains in the GenBank database, specific primers were used to amplify the elongation factor 1α (EF1α) gene region of about 1500kb from PB31. Purified PCR products were cloned using pJET1.2 / blunt vectors (Fisher Scientific, USA). Plasmid DNA extracted from 3-5 clones was sequenced to verify the amplified region. The sequence of each clone from the PB31 EF1α region showed several polymorphisms in the upper 5' flanking region of the gene coding sequence and in the downstream 3' flanking region of the reference strain. Based on the PB31 EF1α region sequence, the inventors of the present invention decided to use the EF1α promoter and terminator region of about 1000bp as potential recombination flanks in the PB31 transformation experiment of the present invention.

[0181] The protein sequences of the neomycin resistance gene and sucrose invertase gene from Saccharomyces cerevisiae and the bleomycin resistance gene from Streptoalloteichus hindustanus were downloaded from the GenBank database. The protein sequences were codon optimized for optimal expression in PB31 using the codon tables of several publicly available and closely related thraustochytrids. An external supplier (Genewiz Inc, San Francisco, CA USA) was used to synthesize the optimized gene fragments. Plasmid DNA extracted from E. coli transformed with synthetic neomycin, sucrose invertase or bleomycin gene cloned into pJET1.2 / blunt vector was sequenced to confirm the original sequence.

[0182] The PB31 EF1α promoter and terminator elements driving the neomycin resistance gene were assembled into the BamH1-cut PUC19 vector using NEB assembly master mix (New England Biolabs, USA) and named pPB0128. The construct pPB0128 for transformation into PB31 can be written as

[0183] pPB0128-PB31EF1a::neoR(s)::PB31EF1a.

[0184] Fig. 9 The sequence of the transforming DNA contained in pPB0128 is shown in . The two BamH1 restriction sites used to generate linear DNA for transforming the cassette into PB31 are indicated in lowercase bold at the beginning and end of the sequence. The underlined sequences at the 5' and 3' flanks of the construct represent genomic DNA from PB31, which can target the integration of the transforming DNA through homologous recombination in the EF1α region. The 5' flank also serves as a promoter region to drive the expression of a downstream neomycin resistance gene that has been codon-optimized for expression in PB31, which allows the strain to grow in the presence of neomycin selection. ScNeo R The initiator ATG and terminator TGA of the gene are indicated in uppercase italics, while the coding region is indicated in lowercase italics. R This is followed by the underlined 3' flank of EF1α which also contains the terminator region of the gene.

[0185] The inventors of the present invention have also produced plasmids pPB136 and pPB240 containing sucrose invertase or bleomycin as marker genes. These constructs can be written as:

[0186] pPB0136-PB31EF1a::ScSUC2::PB31EF1a

[0187] pPB0240-PB31EF1a::ble::PB31EF1a.

[0188] They have the same 5' and 3' EF1a flanking sequences as pPB0128, except that pPB0136 and pPB0240 contain either a sucrose invertase (pPB0136) or a zeocin gene (pPB0240) marker gene instead of neomycin sandwiched between the PB31 EF1a flanks. Fig.10 and 11 The sequences of the sucrose invertase and bleomycin genes contained in plasmids pPB0136 and pPB0240 are shown in FIG.

[0189] Plasmid pPB0128, pPB0136 and pPB0240 are introduced into PB31 by improved lithium acetate (LiAc) transformation method. In brief, 50ml PB31 cell cultures grown overnight in growth medium are collected by centrifugation, and washed with 5ml washing solution (0.1M LiAc and 1x Tris EDTA (pH 8.0). Cell culture is centrifuged at 3750rpm, and supernatant is discarded. Cell pellet is resuspended with 500ml-1000ml washing solution, and incubated on orbital shaker for 1 hour at room temperature. 150ml cell suspension is transferred to the aseptic Eppendorf tube (Eppendorf tube) containing 12-15μg aseptic digestion DNA, and incubated on orbital shaker for 30 minutes at room temperature. Simulation conversion without DNA is also set as a control. 750μl PEG solution (0.1M LiAc+1x TE+40% PEG-4000) is added to the Eppendorf tube, and incubation is continued overnight on an orbital shaker at room temperature. After incubation overnight, cells are collected by centrifugation. Optionally, before collecting cells, cells incubated overnight can be further incubated in a 42°C water bath for 10-15 minutes. After discarding the supernatant, 100-180 μl of growth medium is added to the cells. Depending on the construct introduced, primary transformants are selected for heterotrophic growth on a culture medium containing appropriate selections. Cells transformed with pPB0128 (containing a neomycin resistance gene) and pPB0240 (containing a bleomycin gene) are spread onto an agar plate containing glucose as a carbon source with neomycin or zeocin selection using glass beads. Cells transformed with pPB0136 (containing a sucrose invertase gene) are spread onto an agar plate containing sucrose as the sole carbon source.

[0190] After 2-3 days, colonies began to appear on the plates containing cells transformed with pPB0128 and pPB0240, while colonies on the plates containing pPB0136 took more than 10-14 days. No colonies formed on the plates containing mock-transformed cells. The following table summarizes the results of various transformations of PB31 with pPB0128, pPB0136 and pPB0240 (Table 8).

[0191] [Table 8]

[0192] After transformation of PB31 with pPB0128, pPB0136, and pPB0240, colonies formed on each plate.

[0193]

[0194] Single colonies were clonally purified and the insertion of the various marker genes at the EF1α locus was verified by PCR amplification and sequencing of the regions flanking the integration site.

[0195] Disruption of the EF1α gene had no noticeable effect on the growth pattern of engineered PB31, suggesting that this locus can be used as a neutral site for integration of heterologous gene cassettes to modulate fatty acid composition in subsequent experiments.

[0196] The above examples establish several facts which are summarized below:

[0197] 1. PB31 can be transformed efficiently and reproducibly using the modified LiAc transformation method described in this example.

[0198] 2. Homologous recombination occurs in PB31 and can be used as a tool to modulate various enzyme activities through gene knockdown, knockout, and knockin.

[0199] 3. Homologous recombination in PB31 can be used to enhance or inhibit target gene activity by replacing endogenous regulatory elements with up-regulated or down-regulated heterologous regulatory elements,

[0200] 4. Specific point mutations can be introduced into endogenous enzymes to affect changes in the catalytic activity of the target enzyme, thereby generating enhanced product profiles or even novel products, and

[0201] The best combination of 5.2-4 will produce a novel product profile in PB31.

[0202] 2. Disruption of the fatty acid synthase gene in PB31 leads to enhanced PKS-dependent accumulation of DPA and DHA

[0203] Having established a robust PB31 transformation method, efforts were next made to modulate polyunsaturated fatty acid levels in PB31 and it was decided to disrupt the fatty acid synthase (FAS) gene in PB31 using a neomycin resistance marker.

[0204] This example describes the construction of a recombinant plasmid, pPB0152, containing the fatty acid synthase region amplified from PB31 and the Saccharomyces cerevisiae neomycin resistance gene (neoR) coupled to a PB31 elongation factor 1α terminator gene fragment amplified from pPB0128 (Example 1 above).

[0205] Use the primer of the genomic sequence of the closely related bacterial strain in the Genbank database, amplify the upper 5 ' flanking region of fatty acid synthase (FAS) gene coding region from PB31 bacterial strain.Then, use pJET1.2 / blunt vector (Fisher Scientific Company of the U.S.) to clone the purified PCR product.The plasmid DNA extracted from 3-5 clones is sequenced to verify the amplified region.The sequence from each clone in PB31 FAS district shows several polymorphisms at the upper 5 ' flanking region of gene coding sequence and from reference strain and from the downstream 3 ' flanking region of PB31 clone, which shows 2 copies of the FAS gene with several polymorphic bases in the upper 5 ' flanking region.Build pPB0152 to destroy and lower the expression of PB31 FAS gene.Based on the upper 5 ' flanking FAS district sequence of PB31, the 5 ' flanking FAS district of about 852bp is designated as the promoter of allele 1, and about 1013bp is designated as the promoter of allele 2. Also amplified 804bp FAS3 ' flanking region 500bp downstream from the translation start point of FAS gene, make final construct (pPB0152) contain FAS allele 1 as 5 ' flank and 804bp downstream FAS side as 3 ' flank, thus from FAS coding region, lack 500bp, and when transforming and being integrated into PB31 genome, it is destroyed.Plasmid pPB0152 is by using NEB to assemble master mix (New England Biolabs, U.S.) 852bp FAS allele 1, neomycin resistance gene, EF1α terminator region and FAS 3 ' flank are assembled into the pUC19 cloning vector containing (BamH1) restriction site and build.852bp PB31 FAS 5 ' flank serves as promoter, thus drives the downstream expression of neomycin resistance gene.Finally pPB0152 construct can be written as:

[0206] pPB0152-PB31 FAS 5' flank::Neo(R)-EF1a terminator::PB31 FAS 3' region.

[0207] Figure 12 describes the sequence of plasmid construct pPB0152 with BamH1 restriction site, for cloning and producing the linear DNA for conversion, and the sequence is represented in lowercase bold.The capitalized underlined sequence at the beginning and end of the construct represents PB31 allele 1FAS 5' flank and PB31FAS 3' flank, which can realize the targeted integration of transforming DNA by homologous recombination at the FAS locus, thereby allowing the destruction of the allele 1 of the PB31FAS gene.Carry out in 5' to 3' direction, PB31FAS 5' flank acts as a promoter, thereby driving the expression of the neomycin resistance gene represented in lowercase italics.The initiator ATG and terminator TGA of neo (R) are represented in uppercase italics.Following the neomycin coding sequence is the terminator region from PB31EF1α represented in small capital letters.PB31FAS 3' flanking region (a part of FAS CDS) is represented in uppercase underlined letters. The final construct was sequenced to ensure the correct reading frame and targeting sequence.

[0208] To determine its effect on fatty acid profile, pPB0152 was transformed into PB31 and primary transformants were selected on growth media containing neomycin. Single clonally purified colonies were grown in shake flasks under standard lipid production conditions. The fatty acid profiles of lipids measured by shake flasks of representative derivative lines produced by transformation of wild-type PB31 with pPB0152 are shown in Table 9.

[0209] [Table 9]

[0210] Fatty acid profile as a percentage of total fatty acids from a representative derivative PB31 line transformed with plasmid pPB0152.

[0211]

[0212] ND—Not Detected

[0213] Disruption of FAS allele 1 in PB31 caused subtle but noticeable changes in the fatty acid profiles in the derivative transgenic lines. Representative derivative lines PB31;152-1, PB31;152-2, and PB31;152-3 showed increases in DPA (C22:5n6; 7.8%, 6.91%, and 8.48%, respectively, relative to 5.54% for wild-type PB31) and DHA (C22:6n3; 35.55%, 35.21%, and 40.27%, respectively, relative to 33.28% for wild-type PB31). The increase in DPA and DHA came at the expense of C14:0 and C16:0, which showed consistent decreases in all representative derivative lines. C14:0 and C16:0 were significantly reduced in PB31;152-3, showing the highest DPA and DHA seen in this group of derivative lines compared to wild-type PB31. This data strongly suggests that disruption of the FAS gene in PB31 results in decreased C16:0 synthesis in the derivative line, with an increase in PKS-derived DPA and DHA. PB31;152-1 and PB31;152-3 were stored as Phycoil engineered strains PES-100 and PES-101, respectively.

[0214] 3. Introducing specific point mutations into the polyunsaturated fatty acid synthase (Pfs) B gene in PB31 caused the recombinant strain to produce low or no C22:5n6

[0215] From PB31 genomic DNA, amplify about 1500 base upstream regions and part of polyunsaturated fatty acid synthase (Pfs) B coding region.The PCR product through amplification is purified, and is connected in the blunt vector (pJET1.2), and is transformed into competent cells.Extract plasmid DNA and order-check, to compare and confirm the locus of reference genome sequence from Genbank.Three point mutations are introduced in the coding sequence of Pfs B to change specific amino acids.Introduce the first sudden change to convert the phenylalanine at 65 bases from the starting translation point into leucine (F65L), and introduce the second sudden change to convert the phenylalanine at 230 bases from the translation starting point into leucine (F230L), and introduce the third sudden change to convert the isoleucine at 231 bases from the translation starting point into threonine (1231T). It was recently reported that when these mutations were introduced into Aurochrysalis OH4, the DHA synthase gene initiated EPA production in a heterologous E. coli host (Hayashi et al., 2019). However, the functionality and specificity of these mutations for EPA production in a Thraustochytridaceae host have not been demonstrated. Efforts were made to test the effects of these mutations in the PB31 Thraustochytridaceae host strain of the present invention, and plasmid pPB0218 was constructed for this purpose. The construct pPB218 introduced for expression in PB31 can be written as

[0216] pPB0218-PB31_4-2pfsBp 5' flank: ScNeo-ApBicistronic signal: PB31_4-2PfsBF65LF230L I231T ORF 3' flank.

[0217] Fig.13The sequence of plasmid pPB0218 is shown in . The NotI restriction endonuclease site for producing linear DNA and for cloning is represented with lowercase bold, and defines the 5' and 3' ends of transforming DNA. The underlined capitalized text at the 5' and 3' flanks of the construct represents the genomic DNA from the thraustochytridaceae PB31, which can be targeted for integration of transforming DNA by homologous recombination of the pfs B allele 2 locus. The 5' flank acts as a promoter to drive the expression of downstream neomycin phosphotransferase II gene (Neo, codon optimized for expression in protozoa (A. Protothecoides) and encoding neomycin phosphotransferase II, thus enabling bacterial strains to grow on aminoglycoside antibiotics G418). The initiator ATG and terminator TGA of Neo are represented with uppercase italics, and the rest of the sequence is represented with lowercase italics. The neomycin coding sequence is followed by a 101 nucleotide sequence from Chlorella protothecoides in small uppercase letters to act as a bicistronic signal, allowing the production of neomycin and mutant Pfs B allele 2 proteins from a single transcript. Immediately following this bicistronic sequence is the 3'pfs B flank containing the F65L, F230L and 1231T mutations. The final construct is sequenced to ensure the correct reading frame and targeting sequence. Once transformed and integrated into the PB31 genome, it is envisioned that the Pfs B protein with the desired modification will be produced in the recombinant strain selected for neomycin resistance.

[0218] pPB0218 was transformed into the PB31 Thraustochytridaceae strain and primary transformants were selected on growth medium supplemented with G418. Single clonally purified colonies were grown in shake flasks under standard lipid production conditions. The resulting profiles of a representative set of derivative clones generated by transformation with construct pPB0218 are shown in Table 10.

[0219] [Table 10]

[0220] Fatty acid profile as a percentage of total fatty acids from a representative derivative PB31 line transformed with plasmid pPB0218.

[0221]

[0222] The introduction of the F65L F230L I231T mutation in Pfs B allele 2 in PB31 did not cause enhanced accumulation of EPA in the derivative transgenic strains (Table 10), which is contrary to the reported results obtained in the heterologous host E. coli (Lin et al., 2019). However, DPA was significantly reduced in all derivative transgenic lines. With the exception of PB31;218-4, which produced 3.3% DPA, all derivative transgenic lines produced less than 2% DPA compared to 5.3% DPA in the PB31 parent. Compared with the control PB31, PB31;218-5, PB31;218-9, and PB31;218-13 produced the lowest amount of DPA (1.16%, 0.95%, and 0.86%, respectively). With the exception of PB31;218-13, there was a very slight decrease in DHA in the derivative lines, while C16:0 levels increased slightly. In the derivative line PB31;218-13, a significant reduction in DPA and DHA levels was closely associated with an increase in C16:0. These results demonstrate that the F65L F230L and I231T mutations can modulate Pfs B activity in PB31, resulting in the production of DHA oil containing very low amounts of DPA. PB31;218-5, which produced 1.16% DPA, was stored as Phycoil engineered strain PES-102 and used as the parent strain in subsequent experiments. Since pPB0218 targeted the introduction of F65LF230L and I231T mutations at Pfs B allele 2, it was hypothesized that the unmutated allele 1 of Pfs B was likely the cause of the remaining DPA seen in the derivative transgenic lines. To further reduce DPA levels, another construct (pPB0258) was made that introduced the same F65L F230L and I231T mutations at Pfs B allele 1. For this construct, the bleomycin gene from Streptoalloteichus hindustanensis was used as a selectable marker. The construct pPB0258 can be written as:

[0223] pPB0258-PB31_4-1pfsBp 5' flank:ble-ApBiscistronic signal:PB31_4-2PfsBF65LF230L I231T ORF 3' flank.

[0224] Fig.14The sequence of plasmid pPB0258 is shown in . The NotI restriction endonuclease site for producing linear DNA and for cloning is represented with lowercase bold, and defines the 5' and 3' ends of transforming DNA. The underlined capitalized text at the 5' and 3' flanks of the construct represents the genomic DNA of Thraustochytriaceae PB31, which can be targeted for integration of transforming DNA by homologous recombination at the pfs B allele 1 locus. The 5' flank acts as a promoter to drive the expression of downstream bleomycin (Ble, codon-optimized expression for PB31, and enables bacterial strains to grow on phleomycin selection). The initiator ATG and terminator TGA of Ble are represented with uppercase italics, and the rest of the sequence is represented with lowercase italics. The bleomycin coding sequence is followed by 101 nucleotide bicistronic signals represented with small uppercase letters from the original Chlorella, thereby allowing the production of bleomycin and mutated Pfs B allele 1 albumen from a single transcript. This bicistronic sequence is followed by a 3' pfs B flank containing the F65L, F230L and I231T mutations. The final construct was sequenced to ensure the correct reading frame and targeting sequence.

[0225] pPB0258 was transformed into the PES-102 strain and primary transformants were selected on growth medium supplemented with G418 and phleomycin. Single clonally purified colonies were grown in shake flasks under standard lipid production conditions. The resulting profiles of a representative set of derivative clones generated by transformation with construct pPB0218 are shown in Table 11.

[0226] [Table 11]

[0227] Fatty acid profile as a percentage of total fatty acids from a representative derivative PES-102 line transformed with plasmid pPB0258. Derivative transgenic samples PES-102;218-2 and PES-102;218-3 were run twice to confirm the results.

[0228]

[0229] ND—Not Detected

[0230] As hypothesized, the F65L F230L and I231T mutations introduced into both alleles of Pfs B produced strains with little or no DPA. The DPA peaks seen in PES-102;258-2 and PES-102;258-3 were below the level of detection by GC and were not translated into measurable values ​​(Table 10). The PES-102;258-2 and PES-102;258-3 derivative lines were run a second time and similar results were obtained. In summary, the data of the present invention demonstrate that the F65L F230L and I231T mutations introduced into the Pfs B protein in the Thraustochytriaceae PB31 can modulate the polyketide synthase (PKS) system so that DHA oils with very low or no DPA can be produced as desired. It is expected that this ability to produce DHA oils with customized DPA amounts (between 0%-5%) can be further fine-tuned by large-scale control of fermentation conditions. PES-102;258-2 and PES-102;258-3 were stored as Phycoil engineered strains PES-103 and PES-104, respectively.

[0231] The work presented above demonstrates that novel LCPUFAs can be produced by manipulating both FAS and PKS systems.

Claims

1. A method for producing biomass, the method comprising the steps of culturing and fermenting microorganism PB31, which is also named by ATCC Accession No. PTA-123692.

2. The method according to claim 1, wherein the biomass contains 70 to 80 wt% lipids, and the lipids contain 30 to 55 wt% long chain polyunsaturated fatty acids (LCPUFA).

3. The method according to claim 1, wherein the polyunsaturated fatty acid is one or more selected from the group consisting of ARA, EPA, DPA and DHA.

4. The method of claim 1, wherein the culturing and fermentation are carried out heterotrophically by conventional heterotrophic fermentation, closed photobioreactors or open pond systems.

5. The method according to claim 1, wherein the culturing and fermentation are carried out under conditions that produce a light intensity of less than 5 μmol / m 2 ·s optical signal condition. The method of claim 1 , wherein the microorganism is Schizochytrium. The method according to claim 5 , wherein the optical signal is generated by continuous and / or discontinuous light. The method according to claim 5 , wherein the optical signal is generated by light having a full spectrum or light having a specific wavelength.

9. The method according to claim 1, wherein the culturing and fermentation are carried out using a medium containing a carbon source and a nitrogen source.

10. The method according to claim 8, wherein the carbon source is at least one selected from the group consisting of glucose, fructose, galactose, mannose, sucrose, arabinose, xylose, sodium acetate and glycerol.

11. A method for preparing bio-oil, the method comprising the following steps: (1) Cultivate PTA-123692; as well as (2) Collecting the cultured cell biomass, and extracting and separating the bio-oil containing ω-3 and / or ω-6 polyunsaturated fatty acids.

12. The method of claim 11, wherein the bio-oil comprises 30 to 55 wt% polyunsaturated fatty acids based on total fatty acids.

13. The method according to claim 11, wherein the culturing in step (1) is performed in a manner selected from the group consisting of batch culture, fed-batch culture and continuous culture.

14. The method according to claim 11, wherein step (2) further comprises a cell disruption step.

15. The method according to claim 11, further comprising a step (3) of purifying the bio-oil containing the polyunsaturated fatty acids.

16. A method for producing polyunsaturated fatty acids using the microorganism PTA-123692 or a mutant thereof as a commercial scale biotechnology platform.

17. The method according to claim 16, wherein a mutant of PTA-123692 is used, and the long-chain polyunsaturated fatty acid is one or more selected from the group consisting of DPA and DHA in the range of 0-8 wt%.

18. The method according to claim 16, wherein the PTA-123692 has an 18s rDNA sequence of SEQ ID NO:

1.

19. A feed, food, pharmaceutical or cosmetic composition comprising biomass or bio-oil produced by PTA-123692, a concentrate or a dried product thereof.

20. Use of Schizochytrium sp. PB31 (PTA-123692) or a mutant thereof for preparing a commercial-scale biotechnology platform for producing polyunsaturated fatty acids.